Glaukos Stock Sees Its Relative Strength Rating Improve To Key Above-80 Level

Glaukos (GKOS) had its Relative Strength (RS) Rating upgraded from 78 to 81 Thursday. Is Glaukos stock on your watchlist?


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary RS Rating tracks technical performance by showing how a stock’s price action over the last 52 weeks compares to that of the other stocks in our database.

Over 100 years of market history shows that the market’s biggest winners typically have an 80 or better RS Rating in the early stages of their moves. This makes Glaukos stock’s 81 rating noteworthy.

Looking For The Best Stocks To Buy And Watch? Start Here

Is Glaukos Stock A Buy?

Glaukos stock is trying to complete a consolidation with a 99.10 entry. See if Glaukos stock can clear the breakout price in volume at least 40% higher than normal.

The San Clemente, Calif.-based ophthalmic medical technology company saw both earnings and sales growth rise last quarter. Earnings-per-share growth improved from flat to 52%. Revenue growth rose from 11% to 23%.

Glaukos stock earns the No. 37 rank among its peers in the Medical-Products industry group. Staar Surgical (STAA) and Lemaitre Vascular (LMAT) are also among the group’s highest-rated stocks.


Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button